Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Fig. 1

Waterfall plot illustrating response to pembrolizumab therapy in 14 evaluable patients. The area below the lower red dotted line represents partial response (≥30% decrease in the sum of diameters of target lesions compared with baseline), the area between the two red dotted lines represents stable disease, and the area above the upper red dotted line represents progressive disease (≥20% increase in the sum of diameters of target lesions compared with the smallest sum during the study), based on immune-related Response Evaluation Criteria in Solid Tumors

Back to article page